Permanent 100% Antimicrobial Medical Plastic

描述(由申请人提供)：永久性的100%抗菌医用塑料抗击感染是整个医学界的主要目标之一，因为与感染患者的护理相关的指数成本。减少留在医疗机构的患者交叉感染带来的感染的技术创新可以在金钱和生命方面对医疗界产生重大影响。在所有进入医院的患者中，大约有5%到10%的人在医疗机构逗留期间会接触到某种形式的感染。据估计，医院每年花费超过300亿美元，医院感染可能导致超过10万人丧生。统计数据显示，主要由用抗菌肥皂洗手组成的个人卫生没有出现得足够频繁，不足以阻止医疗机构每年承受300亿美元的支出。不幸的是，只含有0.1-1.0%可浸出抗菌添加剂的医疗产品只能提供暂时的抗菌作用，因为通过清洗或擦拭医疗产品表面可以很容易地去除杀菌剂。Bright ton Development在NIH的支持下开发了一种100%永久性抗菌塑料，可用于医疗保健社区的许多医疗产品。在第二阶段，我们将重点探索这一发现作为永久性100%抗菌材料的可行性，并展示其在对抗医疗保健环境中感染方面的优势。布莱顿发展公司将生成所需的数据，以获得100%抗菌产品在美国环保局的注册，并随后将这些产品提供给医疗保健社区。该项目的目标与NIH消除HAI(医疗保健相关感染)的首要任务之一保持一致，HAI在资金和生命方面都有巨大的影响。

DESCRIPTION (provided by applicant): PERMANENT 100% ANTIMICROBIAL MEDICAL PLASTIC Combating infections is one of the major goals of the entire medical community due to the exponential cost associated with care of an infected patient. Technology innovations to reduce infection brought about by cross-contamination of patients staying in healthcare facilities can have major impact to the medical community in terms of both dollars and human lives. Approximately 5% to 10% of all patients entering a hospital will contact some form of infection during their stay at the healthcare facility. It is estimated that hospitals spend over $30 billion annually and over 100,000 lives can be lost as a result of nosocomial infections. Statistics show that personal hygiene consisting mainly of hand washing with antimicrobial soaps does not occur frequently enough to prevent the $30 billion dollar expenditure that healthcare facilities endure on an annual basis. Unfortunately, medical products containing only 0.1-1.0% of leachable antimicrobial additives only provide temporary antimicrobial action because the biocidal agent can be easily removed by washing or wiping the surface of the medical product. Brighton Development has developed with NIH support a 100% permanent antimicrobial plastic that can be used in numerous medical products found in the healthcare community. In Phase II, we would like to focus on exploiting the feasibility of this discovery as a permanent 100% antimicrobial material and demonstrate its advantages in combating infection in the healthcare environment. Brighton Development will generate the required data to obtain registration of the 100% antimicrobial products with the EPA and subsequently provide these products to the healthcare community. The goals of this project are in alignment with one of NIH top priorities of HAI elimination (Healthcare-associated Infections) that has dramatic impact in terms of both dollars and human lives.